1000025-92-2 Usage
Description
3,5-bis-benzyloxy-pyridine-2-carbonitrile is a pyridine derivative with the molecular formula C21H15N3O2. It features two benzyloxy substituents and a cyano group attached to the 2-carbon of the pyridine ring. This chemical compound is known for its unique structure and properties, making it a valuable intermediate in organic synthesis and medicinal chemistry for the preparation of various pharmaceuticals and bioactive molecules.
Uses
Used in Organic Synthesis:
3,5-bis-benzyloxy-pyridine-2-carbonitrile is used as a building block for the synthesis of diverse compounds with potential biological activity. Its versatile reactivity and functional groups allow for the development of new chemical reactions and synthetic methodologies.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3,5-bis-benzyloxy-pyridine-2-carbonitrile serves as a key intermediate in the preparation of pharmaceuticals. Its unique structure contributes to the creation of bioactive molecules that can be further optimized for therapeutic applications.
Used in Pharmaceutical Development:
3,5-bis-benzyloxy-pyridine-2-carbonitrile is utilized in the pharmaceutical industry as a precursor for the synthesis of various drugs. Its presence in the molecular structure can enhance the pharmacological properties of the final product, making it an essential component in drug discovery and development processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1000025-92-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,0,0,2 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1000025-92:
(9*1)+(8*0)+(7*0)+(6*0)+(5*0)+(4*2)+(3*5)+(2*9)+(1*2)=52
52 % 10 = 2
So 1000025-92-2 is a valid CAS Registry Number.
1000025-92-2Relevant articles and documents
COMPOUNDS HAVING HEPATIAL DISEASE EFFECTIVE
-
Paragraph 0140-0141; 0147, (2021/01/29)
The invention discloses a compound with a hepatopathy curative effect, and the compound is a compound shown as a general formula (I), an optical isomer or pharmaceutically acceptable salt thereof, canbe applied to treatment or prevention of hepatopathy, particularly to drugs for treating or preventing fatty liver, liver fibrosis or liver cirrhosis, and has a good application prospect.
EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO
-
Paragraph 0548; 0549, (2017/08/01)
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
